Principal Financial Group Inc. Has $11.60 Million Position in Momenta Pharmaceuticals, Inc. (MNTA)

Principal Financial Group Inc. increased its stake in shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 3.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 638,832 shares of the biotechnology company’s stock after buying an additional 21,142 shares during the quarter. Principal Financial Group Inc. owned 0.82% of Momenta Pharmaceuticals worth $11,595,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. BlackRock Inc. lifted its position in shares of Momenta Pharmaceuticals by 2.7% during the 1st quarter. BlackRock Inc. now owns 10,755,588 shares of the biotechnology company’s stock worth $195,213,000 after buying an additional 282,272 shares during the period. Palo Alto Investors LLC lifted its position in shares of Momenta Pharmaceuticals by 1.5% during the 4th quarter. Palo Alto Investors LLC now owns 1,821,576 shares of the biotechnology company’s stock worth $25,411,000 after buying an additional 26,578 shares during the period. Renaissance Technologies LLC lifted its position in shares of Momenta Pharmaceuticals by 9.3% during the 4th quarter. Renaissance Technologies LLC now owns 1,583,000 shares of the biotechnology company’s stock worth $22,083,000 after buying an additional 134,500 shares during the period. Tocqueville Asset Management L.P. lifted its position in shares of Momenta Pharmaceuticals by 243.6% during the 4th quarter. Tocqueville Asset Management L.P. now owns 963,784 shares of the biotechnology company’s stock worth $13,445,000 after buying an additional 683,296 shares during the period. Finally, Northern Trust Corp lifted its position in shares of Momenta Pharmaceuticals by 0.4% during the 1st quarter. Northern Trust Corp now owns 922,744 shares of the biotechnology company’s stock worth $16,748,000 after buying an additional 4,018 shares during the period. Institutional investors and hedge funds own 94.76% of the company’s stock.

Shares of Momenta Pharmaceuticals opened at $20.45 on Friday, according to Marketbeat. Momenta Pharmaceuticals, Inc. has a 52-week low of $11.85 and a 52-week high of $24.90. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of -17.04 and a beta of 1.65.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by ($0.19). Momenta Pharmaceuticals had a negative net margin of 88.77% and a negative return on equity of 28.56%. The business had revenue of $4.85 million during the quarter, compared to the consensus estimate of $15.63 million. During the same quarter in the previous year, the firm posted ($0.46) EPS. The company’s revenue for the quarter was down 81.8% compared to the same quarter last year. equities research analysts expect that Momenta Pharmaceuticals, Inc. will post -1.89 earnings per share for the current year.

In other Momenta Pharmaceuticals news, Director Elizabeth Stoner sold 3,399 shares of Momenta Pharmaceuticals stock in a transaction on Tuesday, April 10th. The stock was sold at an average price of $19.00, for a total value of $64,581.00. Following the completion of the transaction, the director now owns 22,777 shares in the company, valued at approximately $432,763. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Craig A. Wheeler sold 43,334 shares of Momenta Pharmaceuticals stock in a transaction on Tuesday, April 10th. The shares were sold at an average price of $19.00, for a total value of $823,346.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 205,907 shares of company stock valued at $4,294,717. Corporate insiders own 4.80% of the company’s stock.

Several equities analysts recently commented on MNTA shares. BidaskClub downgraded Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 27th. ValuEngine upgraded Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, April 3rd. TheStreet downgraded Momenta Pharmaceuticals from a “c-” rating to a “d” rating in a research report on Tuesday, May 8th. Zacks Investment Research downgraded Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, May 21st. Finally, Cantor Fitzgerald started coverage on Momenta Pharmaceuticals in a research report on Monday, June 11th. They set a “hold” rating and a $24.00 target price for the company. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $16.11.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.

Want to see what other hedge funds are holding MNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply